Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and engineering the radio-immuno-conjugate and antibody drug conjugates (ADC) products using its proprietary platform in addition to immune-oncology vaccines. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics’ (CSE:DTC) receives U.S. patent covering its ADC Platform technology

John Ballem  August 8, 2022

Defence Therapeutics Receives U.S. Patent Covering Its ADC Platform Technology

Newsfile August 8, 2022

Defence Therapeutics' (CSE:DTC) AccuTOX shown to kill cancer cells

Trevor Abes  August 2, 2022

Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage

Newsfile August 2, 2022

Defence (CSE:DTC) advancing its anti-cancer drug

Caroline Egan  July 5, 2022

Defence's Accum(TM) with Antibody Drug Conjugates (ADC) in Development Against Cancer

Newsfile July 5, 2022

Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination

Newsfile June 27, 2022

Defence Therapeutics (CSE:DTC) reports that AccuVAC-PTE7 vaccine provides protection from cervical cancer

Azuka Onwuka May 18, 2022

RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

Newsfile May 18, 2022

Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

Newsfile May 17, 2022

Defence Therapeutics (CSE:DTC) receives U.S. patent for its vaccine platform technology

John Ballem  April 7, 2022

Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology

Newsfile April 7, 2022

Defence Therapeutics: An Anti-Cancer Solutions Platform Company Advancing Its Versatile Accum Technology

Newsfile March 22, 2022

Defence Releases Peer-Reviewed Publication of Its Preclinical Data on AccuVAC-D001L In Cell Reports Medicine Journal

Newsfile February 28, 2022

Defence Retains CATO SMS to Advise on Its Phase I Clinical Trial on AccuTOX(TM) for Breast Cancer

Newsfile February 16, 2022

Defence's Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9

Newsfile January 26, 2022

Defence Therapeutics (CSE:DTC) begins IND-enabling testing of Its AccuTOX lead compound against breast cancer

John Ballem  January 10, 2022

Defence Therapeutics Achieves a Major Milestone and Begins IND-Enabling Testing of Its AccuTOX Lead Compound Against Breast Cancer

Newsfile January 10, 2022

Defence Therapeutics (CSE:DTC) Accum boosts delivery effectiveness of the CRISPR/Cas9 protein

John Ballem  December 13, 2021

Defence Therapeutics Accum(TM) Boosts by 9-Fold the Delivery Effectiveness of the CRISPR/Cas9 Protein to Target Cells

Newsfile December 13, 2021